We have more than 65 years of work in Russian market. All the while, we have been committing to the main strategy, which is based on traditionally close relationship with Russian healthcare professionals, as well as the obligation to provide the latest therapies, products of the highest quality for a wider group of people in Russia.

In 1999, the Russian representative office in Moscow was officially registered and the whole range of products was imported through our partners. In 2013 we changed of business strategy in Russia and started the transition from direct contracts’ model to independent commercial activity. Since April 2017, import of all product portfolio in Russia, as well as its storage, sales and marketing have been entirely implemented through Russian legal entity - EGIS-RUS LLC. This step is designed to ensure transparency of operations, financial stability and further strengthen our positions in our strategic region.

The portfolio of EGIS-RUS consists of more than 50 products, which are widely used in cardiology, psychiatry and neurology, allergology, gynecology and other areas of medicine. At the same time, almost half of the portfolio is included in the Russian Vital and Essential Drugs List, that ensures the Russian patients availibility of our products.